MNMD May 2024 8.000 put
| Previous Close | 0.2000 |
| Open | 0.1500 |
| Bid | 0.1500 |
| Ask | 0.2500 |
| Strike | 8.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.1000 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 768 |
Business WireMindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
NEW YORK, May 04, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from MMED008, its Phase 2b study of MM120 (lysergide d-tartrate) in the treatment of GAD in adults. MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. The study was presented
Business WireMindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
NEW YORK, May 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the first quarter ended March 31, 2024.
Business WireMindMed to Present at Upcoming May Medical Conferences
NEW YORK, April 25, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
